PALEXIA RETARD 150 mg PROLONGED-RELEASE TABLETS

2. What you need to know before taking PALEXIA retard 150 mg

Do not take PALEXIA retard 150 mg:

• if you are allergic to tapentadol or any of the other ingredients of this medication (listed in section 6),
• if you have asthma or if your breathing is slow or shallow to dangerous levels [respiratory depression; hypercapnia (elevated carbon dioxide levels in the blood)],
• if you have a disease in which the intestine does not function properly (paralytic ileus),

• if you have consumed alcohol, sleeping pills, other analgesics, or other psychotropic medications (medications that affect mood and emotions) at high doses (see section "Taking PALEXIA retard 150 mg with other medications").

Warnings and Precautions

Consult your doctor or pharmacist before starting to take PALEXIA retard 150 mg:

• if your breathing is slow or shallow,
• if you have increased intracranial pressure or altered consciousness up to coma,
• if you have had a head injury or brain tumors,
• if you have liver or kidney disease (see section "How to take PALEXIA retard 150 mg"),
• if you have pancreatic disease (such as pancreatitis) or biliary tract disease,
• if you are taking medications called mixed opioid agonist/antagonists (e.g., pentazocine, nalbuphine) or partial agonists of opioid μ receptors (e.g., buprenorphine),
• if you are prone to epilepsy or convulsive seizures, or if you are taking other medications with a known risk of increasing seizures, as the risk of these seizures may increase,
• if you or a family member has a history of substance abuse or dependence on prescription medications or illicit substances ("addiction"),
• if you smoke,
• if you have ever had problems with your mood (depression, anxiety, or personality disorder) or have received psychiatric treatment for other mental illnesses.

This medication contains tapentadol, which is an opioid medication. Repeated use of opioid analgesics can lead to tolerance (you may get used to it). It can also lead to dependence and abuse, which can result in a potentially fatal overdose. It is essential to inform your doctor if you think you may have developed dependence on PALEXIA retard 150 mg. Its use (even at therapeutic doses) can cause physical dependence, which may lead to withdrawal symptoms and a recurrence of your problems if you stop taking it suddenly.

PALEXIA retard 150 mg can cause physical and psychological dependence. If you have a tendency to abuse medications or are dependent on medications, you should only take these tablets for short periods under strict medical supervision.

Children and Adolescents

Children and adolescents with obesity should be closely monitored, and the maximum recommended dose should not be exceeded.

Do not administer this medication to children under 6 years of age.

Sleep-Related Breathing Disorders

PALEXIA retard 150 mg can cause sleep-related breathing disorders, such as sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, nighttime awakenings due to difficulty breathing, difficulty maintaining sleep, or excessive daytime sleepiness. If you or someone else observes these symptoms, consult your doctor. Your doctor may consider reducing the dose.

Taking PALEXIA retard 150 mg with Other Medications

Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.

The risk of side effects increases if you are taking medications that can cause seizures (attacks), such as certain antidepressants or antipsychotics. The risk of seizures increases if you take PALEXIA retard 150 mg simultaneously with these medications. Your doctor will tell you if PALEXIA retard 150 mg is suitable for you.

The concomitant use of PALEXIA retard 150 mg and sedative medications, such as benzodiazepines or related medications (certain sleeping pills or tranquilizers [e.g., barbiturates] or analgesics like opioids, morphine, and codeine [also as a cough medication], antipsychotics, antihistamines H1, alcohol), increases the risk of drowsiness, respiratory difficulties (respiratory depression), coma, and can be potentially fatal. Due to this, concomitant use should only be considered when other treatment options are not possible.

However, if your doctor prescribes PALEXIA retard 150 mg with sedative medications, they will limit the dose and duration of concomitant treatment.

The concomitant use of opioids and medications used to treat epilepsy, nerve pain, or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression, and can be potentially fatal.

Inform your doctor if you are taking gabapentin or pregabalin or any other sedative medication, and follow your doctor's dosage recommendation to the letter. It may be helpful to inform your friends and family about the signs and symptoms mentioned above. Inform your doctor if you experience any of these symptoms.

If you are taking a type of medication that affects serotonin levels (e.g., certain medications for treating depression), talk to your doctor before taking PALEXIA retard 150 mg, as there have been cases of "serotonin syndrome". Serotonin syndrome is a rare but potentially life-threatening disorder. Symptoms can include involuntary muscle contractions, including muscles that control eye movement, agitation, excessive sweating, tremors, exaggerated reflexes, increased muscle tension, and body temperature above 38°C. Your doctor can provide additional information.

The concomitant administration of PALEXIA retard 150 mg with other types of medications called mixed opioid agonist/antagonists (e.g., pentazocine, nalbuphine) or partial agonists of opioid μ receptors (e.g., buprenorphine) has not been studied. It is possible that PALEXIA retard 150 mg may not have the same efficacy if administered with one of these medications. Inform your doctor if you are currently being treated with one of these medications.

The administration of PALEXIA retard 150 mg with potent inhibitors or inducers (e.g., rifampicin, phenobarbital, St. John's Wort) of certain enzymes necessary for the elimination of tapentadol from your body may affect the efficacy of tapentadol or cause adverse effects, especially when starting or stopping this other type of medication. Keep your doctor informed about all medications you are taking.

PALEXIA retard 150 mg should not be taken with MAO inhibitors (medications for treating depression). Inform your doctor if you are taking MAO inhibitors or if you have taken them in the last 14 days.

Taking PALEXIA retard 150 mg with Food, Drinks, and Alcohol

Do not consume alcohol while taking PALEXIA retard 150 mg, as some of its side effects, such as drowsiness, may increase. Food intake does not affect the effect of this medication.

Pregnancy and Breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

Do not take this medication:

• if you are pregnant, unless your doctor has indicated it, as tapentadol can cause withdrawal symptoms in the newborn, which can be life-threatening if not detected and treated by a doctor,

• during childbirth, as it can cause slow or shallow breathing to dangerous levels (respiratory depression) in the newborn,
• during breastfeeding, as it can be excreted in breast milk.

Driving and Using Machines

Ask your doctor if you can drive or use machines during treatment with PALEXIA retard. It is essential to observe how this medication affects you before driving or using machines. Do not drive or use machines if you feel drowsy, dizzy, have blurred vision, or have difficulty concentrating. Be particularly careful when starting treatment, after a dose change, or when taking it concomitantly with alcohol or tranquilizers.

PALEXIA retard 150 mg Contains Lactose

If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.

3. How to Take PALEXIA retard 150 mg

Follow the instructions for administration of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

Your doctor will adjust the dose based on the intensity of your pain and your personal sensitivity to pain. Generally, you should take the minimum effective dose to relieve pain.

Adults

The usual starting dose is 50 mg every 12 hours.

Your doctor may prescribe a different dose or dosing regimen, which is more suitable for you if necessary. If you think the effect of these tablets is too strong or too weak, consult your doctor or pharmacist.

Daily doses above 500 mg of tapentadol are not recommended.

Elderly Patients

In elderly patients (over 65 years of age), the dose does not usually need to be adjusted. However, the elimination of tapentadol may be delayed and slower in some patients in this age group. If this applies to you, your doctor may prescribe a different dosing regimen.

Liver and Kidney Diseases (Hepatic and Renal Insufficiency)

Patients with severe liver problems should not take these tablets. If you have moderate liver problems, your doctor will prescribe a different dosing regimen. In cases of mild liver problems, dose adjustment is not necessary.

Patients with severe kidney problems should not take these tablets. In cases of mild or moderate kidney problems, dose adjustment is not necessary.

Use in Children and Adolescents

For children and adolescents from 6 years to less than 18 years, the dose depends on age and body weight.

The suitable dose should be prescribed by your doctor. Do not exceed a total daily dose of 500 mg, i.e., 250 mg administered every 12 hours.

Children and adolescents with kidney or liver problems should not use this medication.

PALEXIA retard 150 mg is not indicated in children under 6 years of age.

How and When to Take PALEXIA retard 150 mg

PALEXIA retard 150 mg should be taken orally.

Always take the tablets whole with a sufficient amount of liquid.

Do not chew, break, or crush them, as this could lead to an overdose because the active substance will be released in your body too quickly.

You can take them on an empty stomach or with food.

The tablet coating may not be completely digested and may appear, apparently unchanged, in the feces. This should not concern you, as the active substance of the tablet will have already been absorbed by the body, and what you see is only the empty coating.

How Long to Take PALEXIA retard 150 mg

Do not take the tablets for longer than your doctor has indicated.

If You Take More PALEXIA retard 150 mg Than You Should

After taking very high doses, you may experience some of the following effects:

• very small pupils, vomiting, decreased blood pressure, rapid heartbeat, fainting, altered consciousness or coma (deep loss of consciousness), seizures, slow or shallow breathing to dangerous levels, or respiratory arrest.

If any of these things happen to you, call a doctor immediately!

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount used. It is recommended to bring the packaging and package leaflet of the medication to the healthcare professional.

If You Forget to Take PALEXIA retard 150 mg

If you forget to take a tablet, you will probably feel pain again. Do not take a double dose to make up for forgotten doses, but continue taking the tablets as before.

If You Stop Taking PALEXIA retard 150 mg

If you stop or discontinue treatment too soon, you will probably feel pain again. If you want to stop treatment, consult your doctor before doing so.

Generally, patients do not experience any side effects after stopping treatment, but in rare cases, people who have taken the tablets for a long time may feel unwell if they stop taking them suddenly.

The symptoms can be:

• restlessness, tearful eyes, runny nose, yawning, sweating, chills, muscle pain, and dilated pupils,
• irritability, anxiety, back pain, joint pain, weakness, abdominal cramps, difficulty sleeping, nausea, loss of appetite, vomiting, diarrhea, and increased blood pressure, respiratory rate, or heart rate.

If you experience any of these symptoms after stopping treatment, consult your doctor.

You should not stop taking this medication abruptly, unless your doctor tells you to do so. If your doctor wants you to stop taking these tablets, they will tell you how to do it, which may involve gradually reducing the dose.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. No additional adverse effects were observed in children and adolescents compared to adults.

Adverse Effects or Important Symptoms to be Aware of and What to Do if You are Affected by Them:

This medicine may cause allergic reactions. The symptoms may consist of wheezing (a kind of whistling when breathing), difficulty breathing, swelling of the eyelids, face, or lips, skin rash, or itching, especially if they affect the whole body.

Another serious adverse effect is breathing more slowly or more weakly than normal. It occurs mostly in elderly patients or in weakened patients.

If you experience any of these important symptoms, consult your doctor immediately.

Adverse Effects that May Occur:

Very Common(may affect more than 1 in 10 people): nausea, constipation, dizziness, drowsiness, headache.

Common(may affect up to 1 in 10 people): decreased appetite, anxiety, depression, difficulty sleeping, nervousness, restlessness, attention disorders, tremors, muscle twitches, hot flashes, shortness of breath, vomiting, diarrhea, indigestion, itching, increased sweating, skin rash, feeling of weakness, fatigue, feeling of change in body temperature, dryness of the mucous membranes, water retention (edema).

Uncommon(may affect up to 1 in 100 people): allergic reaction to medicines (including swelling under the skin, hives, and in severe cases difficulty breathing, decreased blood pressure, collapse, or shock), weight loss, disorientation, confusion, excitability (agitation), perception disorders, sleep disorders, mood elevation, decreased level of consciousness, memory impairment, mental deterioration, fainting, sedation, balance disorders, speech difficulties, numbness, abnormal sensations in the skin (such as tingling, itching), vision disorders, rapid heartbeat, slow heartbeat, palpitations, decreased blood pressure, abdominal discomfort, rash, delayed urination, frequent urination, sexual dysfunction, drug withdrawal syndrome (see section "If you stop treatment with PALEXIA retard 150 mg"), feeling of discomfort, irritability.

Rare(may affect up to 1 in 1,000 people): drug dependence, thought disorders, epileptic seizures, feeling of being about to faint, altered coordination, slow or shallow breathing to dangerous levels (respiratory depression), altered gastric emptying, feeling of intoxication, feeling of relaxation.

Frequency Not Known(the frequency cannot be estimated from the available data): delirium.

In general, the possibility of having suicidal thoughts and behaviors increases in patients with chronic pain. Additionally, some medications for treating depression (with an impact on the brain's neurotransmitter system) may increase this risk, especially at the beginning of treatment. Although tapentadol also affects neurotransmitters, experience in patients has not proven that it increases this risk.

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of PALEXIA retard 150 mg

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the box and on the blister. The expiration date is the last day of the month indicated.

This medicine does not require special storage conditions.

Medicines should not be thrown away through the sewers or in the trash. Deposit the containers and medicines you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.

6. Package Contents and Additional Information

Composition of PALEXIA retard 150 mg

The activeingredient is tapentadol.

Each tablet contains 150 mg of tapentadol (as 174.72 mg of tapentadol hydrochloride).

The othercomponents are:

Core of the tablet: hypromellose, microcrystalline cellulose, anhydrous colloidal silica, magnesium stearate. Film coating of the tablet: hypromellose, lactose monohydrate, talc, macrogol, propylene glycol, titanium dioxide (E 171), yellow iron oxide (E 172), red iron oxide (E 172).

Appearance of PALEXIA retard 150 mg and Package Contents

Prolonged-release tablets, film-coated, pale pink in color, oblong (6.5 mm x 15 mm), with the Grünenthal logo embossed on one side and "H3" on the other.

The tablets are packaged in blisters and supplied in containers of 7, 10, 10x1, 14, 14x1, 20, 20x1, 24, 28, 28x1, 30, 30x1, 40, 50, 50x1, 54, 56, 56x1, 60, 60x1, 90, 90x1, 100, and 100x1 tablets.

Only some package sizes may be marketed.

Marketing Authorization Holder

Grünenthal Pharma, S.A.

Doctor Zamenhof, 36 – 28027 Madrid, Spain

Manufacturer

Grünenthal GmbH

Zieglerstrasse, 6 – D-52078 Aachen, Germany

This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Germany, Austria, Belgium, Cyprus, Croatia, Spain, Greece, Netherlands, Luxembourg, Poland, Portugal, Czech Republic, Slovak Republic: PALEXIA retard

Denmark, Norway, Sweden: PALEXIA Depot

Slovenia, Ireland, United Kingdom (Northern Ireland): PALEXIA SR

Italy: PALEXIA

Date of the Last Revision of this Prospectus:March 2024

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/